Clinical Trial Update: Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for Parvovirus H-1 (ParvOryx) in progressive primary or recurrent glioblastoma multiforme completed Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• Parvovirus H-1 (ParvOryx) (Parvovirus H-1)

Snippet

Sponsor: Oryx GmbH & Co. KG | Conditions: Glioblastoma Multiforme | Phase 1, Phase 2 | Status: COMPLETED